HKG:1652

3 stories mentioning HKG:1652Updated just now

Every FINWIRES story that references HKG:1652, newest first.

Fusen Pharma Unit's Piracetam Injection Gains Marketing Approval in China

Fusen Pharmaceutical (HKG:1652) said its wholly owned subsidiary, Jiaheng Pharmaceutical Technology, received marketing approval in China for Piracetam Injection, according to a Hong Kong bourse filing on Tuesday.The product is approved for treating memory impairment and mild to moderate cerebral dysfunction associated with conditions including cerebrovascular diseases, traumatic brain injury, and toxic encephalopathies.

HKG:1652

Asia35d ago

Fusen Pharma Units Gets China Nod to Market Post-Operative Pain Drug

Fusen Pharmaceutical (HKG:1652) unit Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology obtained marketing approval for Lornoxicam for Injection from China's National Medical Products Administration.The approval is for the indication of the treatment of moderate acute post-operative pain, according to a Monday Hong Kong bourse filing.

HKG:1652

Asia49d ago

Fusen Pharmaceutical Unit Gets Marketing Nod for Progesterone Deficiency Drug in China

Fusen Pharmaceutical (HKG:1652) unit Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology obtained marketing approval for the Dydrogesterone Tablet from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The drug is for the treatment of diseases and symptoms arising from endogenous progesterone deficiency.

HKG:1652

Track with the FINWIRES app suite

FolioX

Track HKG:1652 in your portfolio

WheelAI

Analyze HKG:1652 options with the wheel strategy

StockInsider

See market sentiment on HKG:1652